Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meredith Schramski

Physician Assistant Dearborn, MI Physician Assistant

NPI 1013407261 CMS profile 11109181

18181 Oakwood Blvd Ste 207, Dearborn, MI 48124

Open in the dashboard

General payments

$27,854

148 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Schramski of Dearborn, MI is reported in the CMS Open Payments database as having received $27,854 across 148 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,270 51
2024 General $13,700 50
2023 General $951 26
2022 General $523 13
2021 General $410 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Schramski
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Meredith Schramski were reported at $12,270. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Meredith Schramski Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $410 $132 $37–$438 $132
2022 $523 $155 $48–$522 $149
2023 $951 $167 $52–$557 $160
2024 $13,700 $178 $55–$600 $164
2025 $12,270 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $25,280 72 payments
  2. E.R. Squibb & Sons, L.L.C. $944 35 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $549 15 payments
  4. Boston Scientific Corporation $422 14 payments
  5. AstraZeneca Pharmaceuticals LP $225 2 payments
  6. Lexicon Pharmaceuticals, Inc. $148 3 payments
  7. AltaThera Pharmaceuticals LLC $118 1 payment
  8. Medtronic, Inc. $91 3 payments
  9. Abbott Laboratories $48 1 payment
  10. Sanofi-Aventis U.S. LLC $15 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,000 18 payments
  2. Food and Beverage $4,754 129 payments
  3. Education $100 1 payment
Products named General payments · program years 2021–2025
  1. LifeVest $25,280 72 payments
  2. ELIQUIS $499 27 payments
  3. JARDIANCE Diabetes $362 10 payments
  4. LUX-Dx Insertable Cardiac Monitor $230 5 payments
  5. JARDIANCE Diabetes $187 5 payments
  6. EMBLEM MRI S-ICD $137 2 payments
  7. FARXIGA $125 1 payment
  8. Inpefa $120 1 payment
  9. Sotalol Hydrochloride $118 1 payment
  10. BRILINTA $100 1 payment
  11. Other $294 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,495

Median for Physician Assistant: 241

Drug cost

$633,566

Median for Physician Assistant: $4,110

Branded share of claims

37.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 286 $322,768
Xarelto Rivaroxaban Brand 80 $105,531
Multaq Dronedarone Hcl Brand 50 $77,440
Entresto Sacubitril/Valsartan Brand 59 $69,666
Jardiance Empagliflozin Brand 15 $22,473
Farxiga Dapagliflozin Propanediol Brand 12 $10,845
Metoprolol Succinate Generic 192 $4,101
Amiodarone Hcl Generic 86 $3,259
Flecainide Acetate Generic 61 $2,945
Mexiletine Hcl Generic 21 $2,573

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $173
$173 15 —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $120
$120 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $95
$95 286 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $15
$15 50 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record